1.27M deaths globally were directly attributable to bacterial antimicrobial resistance in 2019¹.
In the U.S., ≥2.8M antimicrobial-resistant infections occur each year and 35,000+ deaths result².
AMR could directly cause approximately 39 million deaths worldwide from 2025 through 2050³.
Unnecessary Prescribing Increases:
Adverse Drug Events
Downstream complications (including C. difficile risk)
Resistance pressure across the community and the health system
A U.S. health-economic model estimated:
Mismanaged acute respiratory infections (ARIs) create massive system cost.
$8.25B/year under standard ARI management
$5.74B/year with FebriDx®-guided management
$2.51B/year Potential savings: ~$2.51B/year
FebriDx® Can Help
It strengthens the “no antibiotic” decision when bacterial infection is unlikely, supporting patient communication and clinician confidence.
-
Easy to use Fingerstick sample
-
~10–15 minute turnaround
-
No analyzer required
-
Simple visual readout
-
Minimal training, no calibration/maintenance
Better patient conversations (and satisfaction)
Patients often request antibiotics “to be safe.”
FebriDx provides a tangible test result clinicians can share to support the treatment plan — helping patients feel heard while reinforcing evidence-based care.
